Christopher Calnan, Staff Writer - Austin Business Journal
Xeris Pharmaceuticals Inc. has received $1.8 million of a planned $1.9 million round of financing.
The Austin-based company collected the capital from 19 investors, according to Wednesday filing with the U.S. Securities and Exchange Commission. The filing was an amendment to a July report to the SEC in which Xeris posted a $1.3 million financing.
Xeris, which was founded last year, develops injectable drugs to treat endocrine and metabolic diseases. Its CEO, John Kinzell, was previously the global head of regulatory affairs for Japan-based Arysta LifeScience Corp.
In February, Xeris announced the appointment of Dr. Steven Prestrelski as its chief scientific officer.
